克服临床试验中更好证据生成的障碍
本文是一篇评论,指出通过增加研究可及性和便利试验参与,可改善代表性人群的临床证据生成;强调需要现代化试验基础设施,将研究拓展到常规实践,并概述了当前障碍、进展领域和所需行动。
要点
- 增加研究可及性和便利试验参与可改善代表性人群的临床证据生成。
- 需要现代化试验基础设施,将研究拓展到更常规的实践中。
- 评论聚焦美国境内医疗产品开发和基础设施问题,旨在具有更广泛的多国适用性。
核心结论
- 需要通过增加研究可及性和便利试验参与,并建设将研究拓展到常规实践的现代化试验基础设施,以改善代表性人群的临床证据生成。
研究设计与样本
- 本文为评论,聚焦美国境内医疗产品(如药物、器械、生物制品)开发和基础设施问题,旨在具有更广泛的多国适用性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical evidence generation from and for representative populations can be improved through increased research access and ease of trial participation. To improve access and participation, a modern trial infrastructure is needed that broadens research into more routine practice. This commentary highlights current barriers, areas of advancement, and actions needed to enable continued transformation toward a modern trial infrastructure for an improved evidence generation system. The focus of this commentary is on the development of medical products (e.g., drugs, devices, biologics) and infrastructure issues within the United States, with the aim to have broader, multi-national applicability.
引用
- Kehoe L, Locke T, McClellan M, et al. Overcoming the barriers to better evidence generation from clinical trials. Trials. 2024. PMID: 39285450. doi:10.1186/s13063-024-08460-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。